Jeb Keiper describes the HKP1 pathway and why he believes his company's expertise in precision engineering and machine learning has...

V.P. of Clinical Operations Jack West gives his interpretation of the announcement that Summit's partner Akeso made in China that it beat...

Bahija Jallal and David Berman go over Immunocore's PRAME data in cutaneous melanoma and explain why they believe that the disease...

Nadim Ahmed describes #ASCO24 data from today for CLN-619 and zipalertinib, and discusses taking a CD19/CD3 into the clinic for lupus.

Tadaaki Taniguchi covers some of the work Astellas is doing with modalities like antibody-drug conjugates, T-cell engagers, and protein degr

Tien Lee describes how TAS2R is a bitter taste receptor that naturally activates gut hormones and gut-brain signaling and can be used to dam

Brian Lortie describes how Blackstone has launched the company and the multiple advantages this relationship brings, why TSLP, and the...

Co-Founder and CEO Taylor Schreiber describes the bi-specific fusion protein construct he is co-inventor of and why he believes it is...

CEO Jon Stonehouse describes how making it across the finish line with Orladeyo has put BioCryst in a position after may decades of drug...

Martin Lehr describes how Nextech enabled this private placement that may allow the company to accelerate clinical development to...

CEO Faheem Hasnian and trial investigator Olivier Sitbon describe how some patients seem to not just be maintaining benefit, but...

John Hood describes how the 12 week data Endeavor is witnessing is giving the company optimism that it might be reversing, rather than...

Leah Fung describes how Biotheryx is leveraging the E3 ligase Cereblon to enable its protein degradation, and discusses the lead CD4/6...

Dr. Matthew Klein provides updates on Translarna, Sepiapterin, Vatiquinone, Utreloxastat, PTC518, and more.

Bernard Coulie gives a deep dive into Pliant's IPF program, including news released this morning relating to patient PET scans.

Ian Mortimer gives the rationale for Kv7 in epilepsy and major depressive disorder, and explains why Xenon has chosen the NaV1.7 sodium...

Yuval Cohen describes why he believe his company's nectin-4 ADC has a next generation design, he covers the idea of integrin inhibition...

Rahul Kakkar describes how PGI is being leveraged for both gene and cell therapy applications.

CEO Mike Severino describes the sickle cell data Tessera is presenting at #ASGCT2024, and highlights the company's gene writing platform...

Ring CEO Tuyen Ong introduces us to anelloviruses and describes the qualities that could make them compelling delivery vehicles. Animal...